Valiant Laboratories Limited
Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopoeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also offers specialty chemicals. The c… Read more
Valiant Laboratories Limited (VALIANTLAB) - Total Liabilities
Latest total liabilities as of September 2025: ₹1.07 Billion INR
Based on the latest financial reports, Valiant Laboratories Limited (VALIANTLAB) has total liabilities worth ₹1.07 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Valiant Laboratories Limited - Total Liabilities Trend (2021–2025)
This chart illustrates how Valiant Laboratories Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Valiant Laboratories Limited Competitors by Total Liabilities
The table below lists competitors of Valiant Laboratories Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Misitano & Stracuzzi S.p.A.
F:O7E
|
Germany | €92.04 Million |
|
D G Khan Cement Company Ltd
KAR:DGKC
|
Pakistan | PKRs68.28 Billion |
|
Phonic Corporation
TWO:3067
|
Taiwan | NT$49.43 Million |
|
Character Group
LSE:CCT
|
UK | GBX32.13 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Valiant Laboratories Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Valiant Laboratories Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Valiant Laboratories Limited (2021–2025)
The table below shows the annual total liabilities of Valiant Laboratories Limited from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹1.67 Billion | +57.38% |
| 2024-03-31 | ₹1.06 Billion | -5.91% |
| 2023-03-31 | ₹1.12 Billion | +1.92% |
| 2022-03-31 | ₹1.10 Billion | +522.33% |
| 2021-03-31 | ₹177.32 Million | -- |